These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18798063)

  • 1. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
    Overman MJ; Kopetz S; Varadhachary G; Fukushima M; Kuwata K; Mita A; Wolff RA; Hoff P; Xiong H; Abbruzzese JL
    Cancer Invest; 2008 Oct; 26(8):794-9. PubMed ID: 18798063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
    Bendell JC; Rosen LS; Mayer RJ; Goldman JW; Infante JR; Benedetti F; Lin D; Mizuguchi H; Zergebel C; Patel MR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):925-32. PubMed ID: 26370544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.
    Overman MJ; Varadhachary G; Kopetz S; Thomas MB; Fukushima M; Kuwata K; Mita A; Wolff RA; Hoff PM; Xiong H; Abbruzzese JL
    Invest New Drugs; 2008 Oct; 26(5):445-54. PubMed ID: 18528634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
    Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
    Johansen M; Zukowski T; Hoff PM; Newman RA; Ni D; Hutto T; Abbruzzeese J; Berghorn E; Hausheer F; Madden T
    Cancer Chemother Pharmacol; 2004 May; 53(5):370-6. PubMed ID: 15060739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.
    Doi T; Ohtsu A; Yoshino T; Boku N; Onozawa Y; Fukutomi A; Hironaka S; Koizumi W; Sasaki T
    Br J Cancer; 2012 Jul; 107(3):429-34. PubMed ID: 22735906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil.
    Becerra CR; Yoshida K; Mizuguchi H; Patel M; Von Hoff D
    J Clin Pharmacol; 2017 Jun; 57(6):751-759. PubMed ID: 28070894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
    Bendell JC; Patel MR; Yoshida K; Seraj J; Weaver R; Lemech C; Todaro TG; Pant S; Arkenau HT
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1275-83. PubMed ID: 27151157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
    Kasi PM; Kotani D; Cecchini M; Shitara K; Ohtsu A; Ramanathan RK; Hochster HS; Grothey A; Yoshino T
    BMC Cancer; 2016 Jul; 16():467. PubMed ID: 27412464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAS-102 for the treatment of metastatic colorectal cancer.
    Salvatore L; Rossini D; Moretto R; Cremolini C; Schirripa M; Antoniotti C; Marmorino F; Loupakis F; Falcone A; Masi G
    Expert Rev Anticancer Ther; 2015; 15(11):1283-92. PubMed ID: 26509228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
    Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
    Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.
    Ravaud A; Cerny T; Terret C; Wanders J; Bui BN; Hess D; Droz JP; Fumoleau P; Twelves C
    Eur J Cancer; 2005 Mar; 41(5):702-7. PubMed ID: 15763645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
    Bando H; Doi T; Muro K; Yasui H; Nishina T; Yamaguchi K; Takahashi S; Nomura S; Kuno H; Shitara K; Sato A; Ohtsu A
    Eur J Cancer; 2016 Jul; 62():46-53. PubMed ID: 27208903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies.
    van der Velden DL; Opdam FL; Voest EE
    Clin Cancer Res; 2016 Jun; 22(12):2835-9. PubMed ID: 27126991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAS-102: a novel antimetabolite for the 21st century.
    Uboha N; Hochster HS
    Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.